Skip to main content

AcelRx Pharmaceuticals, Inc. (ACRX)

NASDAQ: ACRX · IEX Real-Time Price · USD
0.628 0.063 (11.14%)
Dec 7, 2021 11:21 AM EST - Market open
Market Cap74.90M
Revenue (ttm)3.55M
Net Income (ttm)-36.10M
Shares Out119.32M
EPS (ttm)-0.33
PE Ration/a
Forward PE3.62
Dividendn/a
Ex-Dividend Daten/a
Volume599,343
Open0.580
Previous Close0.565
Day's Range0.567 - 0.628
52-Week Range0.540 - 2.940
Beta0.74
AnalystsBuy
Price Target4.17 (+564.3%)
Earnings DateNov 15, 2021

About ACRX

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as...

IndustryPharmaceuticals
IPO DateFeb 14, 2011
CEOVincent Angotti
Employees54
Stock ExchangeNASDAQ
Ticker SymbolACRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ACRX stock is "Buy." The 12-month stock price forecast is 4.17, which is an increase of 564.33% from the latest price.

Price Target
$4.17
(564.33% upside)
Analyst Consensus: Buy

News

AcelRx Pharmaceuticals Announces the Appointment of Jill Broadfoot to its Board of Directors

HAYWARD, Calif., Nov. 23, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies fo...

1 week ago - PRNewsWire

AcelRx To Acquire Lowell For $32M, Announces Capital Raise Of $14M

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has agreed to acquire privately-held Lowell Therapeutics Inc for approximately $32.5 million. The deal consideration includes approximately $26 million of conti...

3 weeks ago - Benzinga

AcelRx Announces $14 Million Registered Direct Common Stock and Warrant Offering

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative the...

3 weeks ago - PRNewsWire

AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

3 weeks ago - PRNewsWire

AcelRx to Host Third Quarter 2021 Financial Results Call and Webcast on November 15, 2021

HAYWARD, Calif., Nov. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release third quarter financial results befor...

3 weeks ago - PRNewsWire

AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

AcelRx Pharmaceuticals to Participate in Two September Investor Conferences

HAYWARD, Calif., Sept. 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative t...

2 months ago - PRNewsWire

Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient...

HAYWARD, Calif., Aug. 30, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

3 months ago - PRNewsWire

Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery ...

HAYWARD, Calif., Aug. 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

3 months ago - PRNewsWire

5 Penny Stocks To Buy According To Top Wall Street Analysts In 2021

Analysts say these are penny stocks to buy. Do you agree?

Other symbols:JAGXRSLSTELLXXII
3 months ago - PennyStocks

AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 0.00% and -19.46%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results

HAYWARD, Calif., Aug. 16, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative th...

3 months ago - PRNewsWire

Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm

New York, New York--(Newsfile Corp. - August 12, 2021) -  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding po...

3 months ago - Newsfile Corp

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals,...

NEW YORK, Aug. 9, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or the "Company") (NASDAQ: ACRX) and certain of i...

3 months ago - PRNewsWire

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. ...

Los Angeles, California--(Newsfile Corp. - August 9, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...

3 months ago - Newsfile Corp

ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Ac...

New York, New York--(Newsfile Corp. - August 9, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...

3 months ago - Newsfile Corp

ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors w...

New York, New York--(Newsfile Corp. - August 9, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) betwee...

3 months ago - Newsfile Corp

AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021

HAYWARD, Calif., Aug. 9, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after...

3 months ago - PRNewsWire

ACRX Final Deadline Monday: Rosen, a Trusted and Leading Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors ...

New York, New York--(Newsfile Corp. - August 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) betwee...

4 months ago - Newsfile Corp

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals...

Los Angeles, California--(Newsfile Corp. - August 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...

4 months ago - Newsfile Corp

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pha...

LOS ANGELES--(BUSINESS WIRE)---- $ACRX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)

4 months ago - Business Wire

MONDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceutical...

Los Angeles, California--(Newsfile Corp. - August 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...

4 months ago - Newsfile Corp

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceutic...

Los Angeles, California--(Newsfile Corp. - August 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AcelRx Pharmaceutical...

4 months ago - Newsfile Corp

ACRX Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class...

New York, New York--(Newsfile Corp. - August 4, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AcelRx Pharmaceuticals, Inc. ("AcelRx" or...

4 months ago - Newsfile Corp

ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Sec...

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) between March 17, 2020 and February...

4 months ago - Business Wire